Social Media Ideas for Egfr T790M

Rare EGFR mutation sharply raises lung cancer risk in large genetic study

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk a...

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Daraxonrasib shows early antitumor activity in RAS-mutant lung cancer

Daraxonrasib, Revolution Medicines tarafından geliştirilen deneysel bir oral RAS inhibitörü, ameliyat dışı NSCLC olgularının yaklaşık üçte birini oluşturan ve PD-1 ek...

Scientists found a rare inherited mutation that dramatically raises lung cancer risk in people who never smoked

Lung cancer is so closely associated with smoking that people who have never smoked may assume their risk is extremely low. But new research has identified a rare inherited genetic...

PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models

Pairing HER3-DXd with the PARP inhibitor olaparib increased DNA damage, induced apoptosis, and slowed tumor progression in vivo in preclinical non-small cell lung cancer models. Th...

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.